Kyverna Therapeutics, Inc. KYTX Finance Lease Liabilities
Finance Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityNoncurrent.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s finance lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s finance lease liabilities?
- Kyverna Therapeutics, Inc. (KYTX) reported finance lease liabilities of $0 in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s finance lease liabilities changed year-over-year?
- Kyverna Therapeutics, Inc.'s finance lease liabilities decreased by 100.0% year-over-year, from $73K to $0.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s finance lease liabilities?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s finance lease liabilities has grown at a -100.0% compound annual growth rate (CAGR), from $921K to $0.
- What does finance lease liabilities mean?
- Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.